€1.6M pre-seed closed

A €1.6M pre-seed round combined €1M in equity from Daphni with €600k of non-dilutive funding from Bpifrance.

The round capitalises the company through target validation and antibody discovery in idiopathic pulmonary fibrosis.

Ian Walters, formerly an executive director at Bristol Myers Squibb, joined the board as an independent board member.